Stock Info

Company Overview

Spyre Therapeutics is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. Spyre’s pipeline includes extended half-life antibodies targeting a4ß7, TL1A, and IL-23.

Latest News
Nov 28, 2023

Spyre Therapeutics, Inc. ("Spyre") (NASDAQ: SYRE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease...

Nov 27, 2023

Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) (the "Company" or "Spyre"), a development-stage biotechnology company, today announced its name change to Spyre Therapeutics, Inc. Effective as of...

Nov 22, 2023

Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel...

View All News

Corporate Presentation

11/30/2023

Spyre Corporate Overview

View All Presentations

Latest Events
Thursday, November 30, 2023
8:20am - 8:40am EST

View All Events

Investor Contact
Investor Email Alerts
* Required Fields